Professional Documents
Culture Documents
DOI 10.1007/s40123-013-0019-y
REVIEW
A. Leonardi (&)
Ophthalmology Unit, Department of Neuroscience, INTRODUCTION
University of Padua, Padua, Italy
e-mail: andrea.leonardi@unipd.it
Allergic conjunctivitis is a localized allergic
condition frequently associated with rhinitis,
but is often observed as the only or prevalent
allergic phenomenon. Ocular allergy can
Enhanced content for this article is involve all of the components of the ocular
available on the journal web site:
www.ophthalmology-open.com surface, including the lid and lid margin,
123
74 Ophthalmol Ther (2013) 2:73–88
conjunctiva and the lacrimal system. The term Africa, Japan, India, and South America but is
allergic conjunctivitis refers to a collection of also reported in North America, China,
hypersensitivity disorders that affect the lid and Australia, Great Britain, and Sweden. VKC
conjunctiva. Various clinical forms are included appears mainly seasonally but can be
in the classification of ocular allergy: seasonal/ perennial, chronic or with acute exacerbations.
intermittent allergic conjunctivitis (SAC), It is an IgE- and T cell-mediated allergic reaction
perennial/persistent allergic conjunctivitis with additional, ill-defined, perhaps
(PAC), vernal keratoconjunctivitis (VKC), nonspecific, hypersensitivity responses. The
atopic keratoconjunctivitis (AKC) and etiology involves a variety of factors, including
drug-induced dermato-conjunctivitis [1]. environmental allergens, climate, and genetic
Corneal involvement is typically restricted to predisposition. Cytologic, biohumoral,
the two most severe forms of ocular allergy, immunohistologic, and molecular biologic
vernal keratoconjunctivitis (VKC) and atopic studies indicate that VKC is a Th2
keratoconjunctivitis (AKC), which requires lymphocyte-mediated disease. Mast cells and
particular care in their management. eosinophils and their mediators play major
The current review focuses on the practical roles in the clinical manifestations. In addition
management of VKC, a recurrent, bilateral, to typical Th2-derived cytokines, Th1-type
chronic allergic inflammatory disease of the cytokines, chemokines, growth factors, and
ocular surface affecting mainly children and enzymes are over-expressed [5]. Increased
young adults and is characterized by serum levels of IL-17 and antinuclear
incompletely identified pathogenic antibodies, together with a high association
mechanisms. Several therapeutic measures with familial history of autoimmune disorders
are required to control signs and symptoms suggest additional mechanisms involved in the
of the disease and avoid potential development of VKC [6, 7]. Tissue remodeling
long-standing or permanent inflammatory reactions, papillae formation of different sizes
sequelae. Although topical anti-allergic and and shapes, stem cell deficiency, and various
anti-inflammatory eye drops are the mainstay degrees of superficial corneal opacification, are
of treatment for VKC, a gold standard further consequences of chronic inflammation
treatment has not yet been established for [8]. Many elements contribute to this dramatic
this disease. response, including epithelial changes,
connective tissue deposition, edema,
inflammatory cell infiltration, and glandular
VERNAL KERATOCONJUNCTIVITIS
hypertrophy.
VKC is a severe inflammatory disease that
appears in children and adolescents with Clinical Forms
seasonal recurrence. It is most often seen in
boys and tends to resolve at puberty. It is a It is well known that two VKC populations can
relatively rare, chronic form of ocular allergy be defined: (1) those with positive test results,
that can cause severe visual complications [2–4]. who generally also present with some other
VKC is more frequent in warmer, arid, windy allergic manifestation, such as asthma, rhinitis,
climates, in the Mediterranean area, central or eczema and (2) those with negative test
123
Ophthalmol Ther (2013) 2:73–88 75
results, and a negative personal and familial PAC, AKC, ocular rosacea in children, and
history of atopy. infectious conjunctivitis, through a
The disease may present in three clinical comprehensive clinical history and
forms: tarsal, limbal and the mixed form. Large ophthalmic examination. It is important to
papillae of different shape and size, usually note that while skin test results may be
greater than 1 mm in diameter, on the upper positive, VKC is not always closely related to
tarsal conjunctiva characterize the tarsal form, allergen exposure, and climate is an equally
while Trantas’ dots and infiltrates on the limbus important factor. Conjunctival scrapings or tear
are typical of the limbal form. The mixed form cytology can be useful, revealing increased
is characterized by the presence of both forms in leukocytes in the conjunctiva, particularly
the same eye. VKC sufferers have a eosinophils [1, 2].
characteristic ropey, stringy mucous and/or
serous discharge, and corneal complications,
MANAGEMENT OF VKC
such as superficial punctate keratopathy (SPK),
and shield ulcers are common. Moderate to Understanding and treating VKC has been a
intense conjunctival hyperemia, intense challenge for ophthalmologists, since the
itching, photophobia, mild to moderate pathogenesis is unclear and anti-allergic
chemosis, foreign-body sensation, and pain are therapy often unsuccessful. VKC is an IgE- and
typical signs and symptoms which may be very T cell-mediated disease, leading to a chronic
intense upon awakening, causing frequently inflammation in which eosinophil, lymphocyte
what is called the morning misery. While it is and structural cell activation characterize the
considered a long-term disease with an average conjunctival allergic reaction. Therefore,
duration of 4–8 years, VKC generally subsides measures aimed at stabilization of mast cells or
before or just after puberty [1, 2, 4]. It can persist histamine receptor antagonists alone are
or reactivate after puberty, however, a VKC-like frequently insufficient for controlling
disease has been found in young adults without conjunctival inflammation and the frequent
any history of allergic disease in childhood [9]. corneal involvement [1, 2]. Currently available
This new clinical entity is characterized by signs drugs may be merely palliative and do not
and symptoms similar to the typical VKC. extinguish the complex immune process that
Allergy test results, cytokine production, and initiates and perpetuates the allergic ocular
quality of life are similar to those in pediatric surface inflammation.
VKC. It is still unclear if this is a sub-type of VKC In a meta-analysis of randomized clinical trials
with a later onset or a different clinical entity. evaluating topical treatments for VKC, only 10 of
21 studies were suitable for statistical analysis,
Diagnosis and the authors concluded that the currently
available topical drugs are effective in treating
VKC is not difficult to diagnose by clinical acute phases of VKC [10]. However, controlling
examination. Trantas’ dots and large VKC signs and symptoms may be a challenge
cobblestone papillae are indicative of the even for expert ophthalmologists. Because of the
condition [1, 2]. VKC is differentiated from chronicity and severity of the disease, avoidance
other ocular allergic conditions, such as SAC, of triggers and life-style planning must be
123
76 Ophthalmol Ther (2013) 2:73–88
123
Ophthalmol Ther (2013) 2:73–88 77
Table 2 Topical ocular allergy medications for the treatment of vernal keratoconjunctivitis
Class Drug Indication Comments
Vasoconstrictor/ Naphazoline/pheniramine Rapid onset Short duration of action
antihistamine of action Tachyphylaxis
combinations Episodic itching Mydriasis
and redness
Ocular irritation
Hypersensitivity
Hypertension
Potential for inappropriate
patient use
Antihistamines Levocabastine Relief of itching Short duration of action
Emedastine Relief of signs and Frequently does not provide complete
symptoms disease control when used alone
Mast cell stabilizers Sodium cromoglicate Relief of signs and Long-term usage
Nedocromil symptoms Slow onset of action
Lodoxamide Prophylactic dosing
NAAGA Frequently does not provide complete
Pemirolast disease control when used alone
Ketotifen
Olopatadine
Corticosteroids Loteprednol Treatment of Risk for long-term side effects
Fluormetholone allergic No mast cell stabilization
inflammation
Desonide Potential for inappropriate patient
Use in moderate use
Rimexolone
to severe forms
Dexamethasone Requires close monitoring
Betamethasone
123
78 Ophthalmol Ther (2013) 2:73–88
eosinophil cationic protein ECP before and with allergic conjunctivitis, including VKC, by
after therapy [17], suggesting that lodoxamide inhibiting proinflammatory cytokine secretion
has an effect on eosinophil activation. from conjunctival epithelial cells [23]. The first-
Inhibition of eosinophil activation and generation antihistamines pheniramine and
degranulation is the proposed mechanism for antazoline have a long safety record, but are
its efficacy against corneal signs such as known for their burn upon instillation, the
keratitis and shield ulcers in severe allergic rapid onset and disappearance of their effects,
disease [17]. Lodoxamide was shown to be and their limited potency [24]. These are still
superior to placebo [18] and N-acetyl aspartyl available in over-the-counter products,
glutamic acid (NAAGA) for treatment of VKC particularly in combination with
[19]. The recommended dosing schedule is four vasoconstrictors.
times daily. Lodoxamide may be used The newer antihistamines are still H1
continuously for 3 months in children older antagonists, but have a longer duration of
than 2 years of age. action (4–6 h), and are better tolerated than
NAAGA 6% has been widely used in Europe their predecessors. These include levocabastine
as topical eye drops in the treatment of VKC hydrochloride 0.5% and emedastine difumarate
[20]. NAAGA is known to inhibit leukotriene 0.05%.
synthesis, histamine release by mast cells, and Levocabastine 0.05% eye drops alone,
complement-derived anaphylatoxin instilled four times daily for 3 months, was
production. This anti-allergic compound was effective, safe, and well tolerated by patients
also shown to directly inhibit leukocyte with VKC; however, it was less effective than
adhesion to endothelial cells induced by lodoxamide [25] or NAAGA [20]. Interestingly,
proinflammatory stimuli, and abrogates tumor in an animal model, levocabastine reduced
necrosis factor a-induced expression of the clinical aspects of the late-phase reaction
adhesion molecules on granulocytes and and the conjunctival expression of
endothelial cells [21]. These pharmacological alpha(4)beta(1) integrin by reducing
properties confer a potential anti-inflammatory infiltration of eosinophils [26].
activity. Emedastine 0.05% appears to be more potent
and selective than levocabastine [27, 28].
Antihistamines Indeed, in direct comparison with
Antihistamines act via histamine receptor (HR) levocabastine, emedastine proved significantly
antagonism to block the inflammatory effects of more effective in alleviating signs of seasonal
endogenous histamine and prevent or relieve allergic conjunctivitis [27, 28]. No specific
the associated signs and symptoms. Most studies in VKC have been performed.
antihistamines used in the treatment of allergy A meta-analysis of randomized clinical trials
are H1 receptor antagonists, although some in VKC showed a large number of studies (20)
agents may have affinity for other receptor evaluated the efficacy of common anti-allergic
subtypes [22]. H2 antagonists have been shown eye drops (levocabastine, lodoxamide,
to modulate both cell growth and migration mipragoside, NAAGA, nedocromil sodium,
[22]. Ocular drugs with antihistaminic activity DCG). Among these, lodoxamide appeared to
may offer therapeutic advantages to patients be the most effective [10].
123
Ophthalmol Ther (2013) 2:73–88 79
123
80 Ophthalmol Ther (2013) 2:73–88
3–5 days. Loteprednol etabonate is usually reduction in IL-5 production, and may reduce
indicated for 7–8 days in the treatment of eosinophil recruitment and effects on the
the acute phase. Prednisolone, conjunctiva and cornea [39]. CsA is lipophilic
dexamethasone, or betamethasone should be and thus must be dissolved in an alcohol-oil
used only when the above-mentioned base [39]. Unavailability of a commercial
first-choice steroids have proven ineffective. preparation of topical CsA, technical
Steroid–antibiotic combination eye drops difficulties in dispensing eye drops and legal
should be avoided, as VKC is an allergic restrictions on its topical use in many countries,
inflammation, rather than an infection. preclude its widespread use for VKC treatment.
Corticosteroids should not be recommended The 2% formulation has the longest track
for long-term use because of possible ocular record, but lower concentrations (1%, 0.5%,
adverse effects, including increases in and 0.05%) have been used and shown to be
intraocular pressure (IOP), induction or effective. So far, there is no general consensus
exacerbation of glaucoma, formation of regarding the minimum effective concentration
cataracts, delayed wound healing, and of CsA. Only the 0.05% formulation is
increased susceptibility to infection or commercially available for the treatment of
superinfection. These adverse effects depend, dry eye.
in part, on the structure, dose, duration of After long cycles of treatment, CsA has a
treatment and gender disposition [36]. In fact, marked steroid-sparing effect, potentially
following daily administration of allowing control of symptomatology without
corticosteroids for 4–6 weeks, approximately steroids [40]. When necessary, additional
one-third of the normal population will be topical steroids can be used in short cycles.
‘‘high or moderate responders’’ with an Systemic absorption of CsA was not detectable
increase in IOP of between 6 and 15 mm Hg by clinical laboratory methods. Burning and
[36]. Forty-one of 145 (28.3%) patients with irritation are frequent side effects. Treatment
severe VKC in a Singapore case series can be prescribed seasonally or perennially,
developed a corticosteroid response, of reducing doses in the non-active phases of the
which eight (5.5%) progressed to glaucoma disease. Adverse events, such as bacterial or viral
[37]. Six of these patients (n = 8 eyes) required infections are rare, while IOP changes have not
trabeculectomy/mitomycin-C. The main risk been reported.
factor for trabeculectomy was a greater CsA 1% or 2% emulsion in castor or olive oil
increase in IOP from baseline, which was instilled four times daily can be considered for
independent of potential confounders such as treatment of moderate to severe VKC and can
type and duration of corticosteroid use [38]. serve as a good alternative to steroids [39, 41].
After 2 weeks, CsA 1% four times daily
Calcineurin Inhibitors and Other significantly reduced signs and symptoms and
Immunomodulators tear levels of ECP in a group of VKC patients
Cyclosporine A (CsA) is effective in controlling [42].
VKC-associated ocular inflammation by CsA 1% was reported to be the minimum
blocking Th2 lymphocyte proliferation and effective concentration in the treatment of
interleukin-2 production. It inhibits histamine shield ulcers, with recurrence observed at
release from mast cells and basophils through a lower concentrations [43]. In a randomized,
123
Ophthalmol Ther (2013) 2:73–88 81
controlled trial, the effects of CsA 0.05% were allergic conjunctivitis. Patients were treated
similar to placebo [44]. Conversely, in another twice daily for 4 weeks. Objective signs,
study, CsA 0.05% decreased the severity of subjective symptoms, giant papillae and
symptoms and clinical signs significantly after corneal involvement were significantly
6 months and the need for steroids was reduced, improved. The most frequent tacrolimus-
suggesting that CsA at low doses is an effective related adverse event was ocular irritation [52].
steroid-sparing agent in VKC [45]. In a clinical In the same study it is also reported that the dose
prospective and observational study in 594 of tacrolimus was based on the results from a
patients, CsA 0.1% was shown to be effective previous dose-ranging study in which
and safe for the treatment of VKC [46]. A recent tacrolimus ophthalmic suspension 0.01%,
systematic review and meta-analysis study 0.03%, and 0.1% were tested. Since 0.1%
suggests that topical CsA is effective and safe showed stronger improvement and similar
for the treatment of VKC, since signs and safety profile compared with 0.01% and 0.03%,
symptoms significantly improve after the 0.1% was considered an optimal dose.
treatment, regardless of the CsA dosage [47]. Documentation on the quality, safety and
A randomized, controlled two-year crossover efficacy of the different preparations used in the
study demonstrated the safety and efficacy of different clinical reports will be necessary before
CsA 0.05% for long-term prevention of VKC tacrolimus is granted orphan medication status
relapses [40]. Patients treated with ketotifen had for VKC.
a risk of recurrences 2.4 times higher than A prospective double-masked randomized
patients treated with CsA. In addition, CsA comparative trial comparing the efficacy of
significantly improved itching, photophobia 0.1% tacrolimus ophthalmic ointment with
and conjunctival hyperemia scores in CsA 2% showed that both were equally
comparison with ketotifen. These data are of effective in the treatment of VKC [53].
great importance for the long-term Short-term, low-dose, topical mitomycin-C
management of pediatric patients at risk of 0.01% has been considered for treating acute
visual impairment, whether due to steroid exacerbations in patients with severe VKC
abuse or to continued recurrences of acute refractory to conventional treatment [54]. A
inflammation [40]. significant decrease in signs and symptoms
Tacrolimus is a potent drug, similar to CsA in compared with the placebo group was shown at
its mode of action, but chemically distinct. A the end of the 2-week treatment period.
tacrolimus skin ointment is licensed for the Unavailability of commercial topical
treatment of moderate to severe atopic eyelid preparations, the short duration of studies, and
diseases and may have secondary benefits for the lack of data on the safety profile and long-term
AKC [48–50]. Conjunctival application of outcomes are major limitations in recommending
tacrolimus ointment 0.03% and 0.1% were mitomycin for the treatment of VKC.
effective, well tolerated, and safe in the
treatment of severe allergic conjunctivitis [49, Topical Non-Ocular Pharmacologic
51]. In a multicenter, randomized, Treatment
double-masked, placebo-controlled clinical
trial, tacrolimus ophthalmic suspension 0.1% The efficacy of intranasal corticosteroids in
was shown to be effective in treating severe treating allergic nasal symptoms is well
123
82 Ophthalmol Ther (2013) 2:73–88
established. Recent data show a promising effect [60]; however, it should be used with caution
of intranasal corticosteroids on ocular because of the well-known possible side effects.
symptoms of allergic rhinoconjunctivitis [55]. In severe cases, systemic treatment with
At the moment, no studies in VKC have been T-lymphocyte signal transduction inhibitors
performed or reported in the literature. The such as CsA or tacrolimus may ameliorate
mechanism by which an intranasal both the dermatologic and ocular
corticosteroid reduces ocular allergic manifestations in severe patients who are
symptoms has been under investigation; some refractory to conventional treatment [61].
effects on both the reflex neural activity and the Omalizumab, an anti-IgE recombinant,
local inflammation, facilitating nasolacrimal humanized, non-anaphylactogenic antibody,
drainage, have been proposed [56]. directed against the receptor-binding domain
Meta-analysis studies showed that there is no of IgE, may be used in VKC patients with high
significant difference in improvement of eye levels of total serum IgE [62].
symptoms between intranasal corticosteroids
and oral antihistamines [57] including Specific Immunotherapy
non-sedating antihistamines. Thus, in VKC
patients with associated nasal symptoms, nasal Allergen-specific immunotherapy (SIT) is
corticosteroids may be beneficial. indicated only when a clearly defined systemic
hypersensitivity to identified allergens exists.
Systemic Pharmacologic Treatment The choice of the allergen to be employed for
SIT should be made in accordance with the
Systemic treatment with oral antihistamines or combination of clinical history and results of
antileukotrienes can reduce the severity of skin prick test and specific serum IgE. Since the
flare-ups and generalized hyper-reactivity. First- development of non-invasive formulations with
generation H1 receptor antagonists may provide better safety profiles, there is an increasing
some relief of ocular itching, but are sedating and tendency to prescribe sublingual
have anticholinergic effects such as dry mouth, immunotherapy (SLIT) in young patients. A
dry eye, blurred vision and urinary retention. systematic review and meta-analysis of
Second-generation antihistamines offer the same double-blind, placebo-controlled randomized
efficacy as their predecessors, but with a low- controlled trials confirmed that SLIT reduces
sedating profile and lack of anticholinergic significantly ocular symptom scores in patients
activity. These drugs include acrivastine, with allergic conjunctivitis with or without
cetirizine, ebastine, fexofenadine, loratadine and rhinitis [63]. The SIT treatment in IgE-positive
mizolastine. However, even their use has been patients with VKC was more effective than
associated with drying effects, particularly of the topical treatment in improving clinical
ocular surface [58]. Desloratadine and symptoms and reducing total serum IgE [64].
levocetirizine are considered a subsequent
evolution of these second-generation agents and Surgical Treatment
are preferred over first-generation antihistamines
for the treatment of allergic conjunctivitis [59]. Supratarsal injection of either a short- or
Aspirin 0.5–1 g per day has been shown as a intermediate-acting corticosteroid has been
steroid-sparing factor in the treatment of VKC proposed as a therapeutic approach to treating
123
Ophthalmol Ther (2013) 2:73–88 83
patients with refractory VKC [65]. Although These and other more invasive procedures
significant symptomatic and clinical such as oral mucosal grafting should be avoided
improvements have been reported, persistent or considered only by ophthalmology experts in
increase in IOP occurred in one of 12 VKC VKC management.
patients [65].
Surgical removal of corneal plaques is PRACTICAL MANAGEMENT OF VKC
recommended to alleviate severe symptoms
and to allow for corneal re-epithelization. Treatment of VKC requires a multi-pronged
Giant papillae excision with intraoperative approach that includes conservative measures
0.02% mitomycin-C followed by CsA topical and the use of drugs, as summarized in Table 3.
treatment may be indicated in cases of Close collaboration between ophthalmologists,
mechanical pseudoptosis or the presence of allergists and pediatricians is recommended.
coarse giant papillae and continuous active Patients and parents should be made aware of
disease [66, 67]. the long duration of disease, its chronic
Cryotherapy and/or excision of giant papillae evolution and possible complications.
should otherwise be avoided because these It is recommended to use a clinical grading
measures treat only the complications and not system to identify the more severe forms of VKC
the underlying disease, and may induce that are at higher risk of recurrences, corneal
unnecessary scarring. Amniotic membrane ulceration, and worsened final visual outcome
transplantation (AMT) following keratectomy [73]. A simple grading system has been
has been described as a successful treatment for proposed to formulate global guidelines for
deep ulcers, in cases with slight stromal treating VKC (Table 4) [73–75].
thinning [68]. The presence of residual The selection of a drug from the many
membrane under the epithelium may affect available options is also based on geographical
postoperative corneal transparency. The area, personal experience and preference of
treatment algorithm for corneal complication the treating physician, since there is no
can be based on the Cameron clinical grading of standard treatment and a lack of evidence to
shield ulcers [69]: Grade 1, ulcers received support choice of drug in the management of
medical therapy alone; Grade 2 and Grade 3 VKC.
ulcers received either medical therapy alone or Topical administration of mast cell
medical therapy combined with debridement, stabilizers, with preference for those which
AMT, or both. Using this approach, it was shown have anti-eosinophil effects such as NAAGA
that Grade 1 ulcers respond well to medical and lodoxamide, should be started at the onset
therapy alone; Grade 2 ulcers occasionally may of the allergic symptoms and used continuously
require additional debridement or AMT; Grade 3 throughout the season. If monotherapy with
ulcers are frequently refractory to medical mast cell stabilizers is not enough to prevent the
therapy and require debridement and AMT for symptoms, antihistamines or multiple-acting
rapid re-epithelialization [70] . drugs such as olopatadine and ketotifen, 2–4
Significant limbal stem cell deficiency as a times a day should be added and continued for
complication of severe and persistent limbal the entire season. Frequent instillations may be
inflammation has been treated with stem cell inconvenient, however, no significant side
transplantation [71, 72]. effects of these drugs have been reported with
123
84 Ophthalmol Ther (2013) 2:73–88
short- or long-term use. Preservative-free they have limited use in VKC management.
formulations should be recommended. Systemic treatment with oral antihistamines or
NSAIDs such as ketorolac, diclofenac and antileukotrienes can reduce the severity of
pranoprofen may be considered as steroid- ocular flare-ups and the nonspecific hyper-
sparing options. However, in clinical practice reactivity typical of these patients. They
123
Ophthalmol Ther (2013) 2:73–88 85
should be started at the onset of symptoms and experiences with tacrolimus have been
used continuously throughout the allergic reported using different preparations and
season. concentrations. It seems to be more effective
Moderate to severe VKC may require than CsA, and also effective in patients
repeated topical steroid treatment to refractory to CsA. Randomized trials of topical
downregulate conjunctival inflammation and tacrolimus are needed.
reduce cellular infiltrate. ‘‘Soft corticosteroids’’ Corneal complications should be carefully
may be considered preferentially as the first monitored and anti-inflammatory therapy
corticosteroid preparations to be used. Dosages adjusted; in these cases, steroids should be used,
are chosen based on the inflammatory state. An since the pathogenesis of the ulcer is strictly
instillation frequency of 4 times per day for immune-mediated. Corticosteroids are preferred
5–10 days is recommended. Prednisolone, over CsA, since they are more effective in
dexamethasone or betamethasone should be inhibiting the inflammatory component of
used as a second-line choice, or as first-line corneal damage (i.e., eosinophil- and neutrophil-
treatment in the most severe cases. A ‘‘pulsed’’ liberated epithelial toxic mediators) [2].
treatment of 3–5 days, in addition to the Severe cases that do not respond to any of
continuous use of mast cell stabilizers and these topical therapies may require treatment
topical antihistamines, is recommended. The with systemic corticosteroids (prednisone
use of ointment at night-time may be helpful in 1 mg/kg per day) for a short period of time.
children when opening the eyes in the morning If a systemic hypersensitivity to identified
is difficult because of photophobia due to the allergens exists, specific immunotherapy may
epitheliotoxicity of released mediators while be considered.
the eyes are closed.
CsA 1% or 2% can be considered for
treatment of moderate to severe VKC. It
ACKNOWLEDGMENTS
decreases the severity of signs and symptoms
Dr. Leonardi is the guarantor for this article,
and the need for steroids. No significant side
and takes responsibility for the integrity of
effects, except for a burning sensation during
the work as a whole. No funding or
administration, have been reported [39]. No
sponsorship was received for the publication
randomized studies on dose–effect differences
of this article.
have been published. In clinical practice, one
drop of CsA 1% from 2 to 4 times a day,
Conflict of interest. Dr. Leonardi declares
depending on the severity of signs and
no conflicts of interest.
symptoms, is effective for controlling the
disease during seasonal exacerbations. Open Access. This article is distributed
Treatment can be suspended during winter under the terms of the Creative Commons
until the first exacerbation of the new season. Attribution Noncommercial License which
Adult patients respond better to CsA compared permits any noncommercial use, distribution,
with any other therapeutic regimen [9]. and reproduction in any medium, provided the
If a patient does not respond to CsA, topical original author(s) and the source are credited.
tacrolimus can be considered. Several
123
86 Ophthalmol Ther (2013) 2:73–88
8. Kumagai N, Fukuda K, Fujitsu Y, et al. Role of 21. Lapalus P, Moulin G, Bayer V, et al. Effects of a new
structural cells of the cornea and conjunctiva in the anti-allergic agent: the magnesium salt of N-acetyl-
pathogenesis of vernal keratoconjunctivitis. Prog aspartyl-glutamic acid on experimental allergic
Retin Eye Res. 2006;25(2):165–87. inflammation of the rabbit eye. Curr Eye Res.
1986;5(7):517–22.
9. Leonardi A, Lazzarini D, Motterle L, et al. Vernal
keratoconjunctivitis-like disease in adults. Am J 22. Bielory L, Ghafoor S. Histamine receptors and the
Ophthalmol. 2013;155(5):796–803. conjunctiva. Curr Opin Allergy Clin Immunol.
2005;5(5):437–40.
10. Mantelli F, Santos MS, Petitti T, et al. Systematic
review and meta-analysis of randomised clinical trials 23. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of
on topical treatments for vernal keratoconjunctivitis. histamine-induced human conjunctival epithelial
Br J Ophthalmol. 2007;91(12):1656–61. cell responses by ocular allergy drugs. Arch
Ophthalmol. 1999;117(5):643–7.
11. Kumar S, Gupta N, Vivian AJ. Modern approach to
managing vernal keratoconjunctivitis. Curr Allergy 24. Yanni JM, Sharif NA, Gamache DA, et al. A current
Asthma Rep. 2010;10(3):155–62. appreciation of sites for pharmacological
intervention in allergic conjunctivitis: effects of
12. Tabbara KF, Arafat NT. Cromolyn effects on vernal new topical ocular drugs. Acta Ophthalmol Scand
keratoconjunctivitis in children. Arch Ophthalmol. Suppl. 1999;228:33–7.
1977;95(12):2184–6.
25. Verin P, Allewaert R, Joyaux JC, et al. Comparison
13. Bonini S, Barney NP, Schiavone M, et al. Effectiveness of lodoxamide 0.1% ophthalmic solution and
of nedocromil sodium 2% eyedrops on clinical levocabastine 0.05% ophthalmic suspension in
symptoms and tear fluid cytology of patients with vernal keratoconjunctivitis. Eur J Ophthalmol.
vernal conjunctivitis. Eye. 1992;6(Pt 6):648–52. 2001;11(2):120–5.
123
Ophthalmol Ther (2013) 2:73–88 87
26. Qasem AR, Bucolo C, Baiula M, et al. Contribution 38. Ang M, Ho CL, Tan D, Chan C. Severe vernal
of alpha4beta1 integrin to the antiallergic effect of keratoconjunctivitis requiring trabeculectomy with
levocabastine. Biochem Pharmacol. 2008;76(6): mitomycin C for corticosteroid-induced glaucoma.
751–62. Clin Exp Ophthalmol. 2012;40(4):e149–55.
27. Secchi A, Leonardi A, Discepola M, et al. An efficacy 39. Utine CA, Stern M, Akpek EK. Clinical review:
and tolerance comparison of emedastine topical ophthalmic use of cyclosporin A. Ocul
difumarate 0.05% and levocabastine Immunol Inflamm. 2010;18(5):352–61.
hydrochloride 0.05%: reducing chemosis and
eyelid swelling in subjects with seasonal allergic 40. Lambiase A, Leonardi A, Sacchetti M, et al. Topical
conjunctivitis. Emadine Study Group. Acta cyclosporine prevents seasonal recurrences of
Ophthalmol Scand Suppl. 2000;230:48–51. vernal keratoconjunctivitis in a randomized,
double-masked, controlled 2-year study. J Allergy
28. Secchi A, Ciprandi G, Leonardi A, et al. Safety and Clin Immunol. 2011;128(4):896–7 e9.
efficacy comparison of emedastine 0.05%
ophthalmic solution compared to levocabastine 41. Pucci N, Novembre E, Cianferoni A, et al. Efficacy
0.05% ophthalmic suspension in pediatric subjects and safety of cyclosporine eyedrops in vernal
with allergic conjunctivitis. Emadine Study Group. keratoconjunctivitis. Ann Allergy Asthma Immunol.
Acta Ophthalmol Scand Suppl. 2000;230:42–7. 2002;89(3):298–303.
29. Hida WT, Nogueira DC, Schaefer A, et al. 42. Leonardi A, Borghesan F, Faggian D, et al.
Comparative study between 0.025% ketotifen Eosinophil cationic protein in tears of normal
fumarate and 0.1% olopatadine hydrochloride in subjects and patients affected by vernal
the treatment of vernal keratoconjunctivitis. Arq keratoconjunctivitis. Allergy. 1995;50(7):610–3.
Bras Oftalmol. 2006;69(6):851–6.
43. Cetinkaya A, Akova YA, Dursun D, Pelit A. Topical
30. Corum I, Yeniad B, Bilgin LK, Ilhan R. Efficiency of cyclosporine in the management of shield ulcers.
olopatadine hydrochloride 0.1% in the treatment Cornea. 2004;23(2):194–200.
of vernal keratoconjunctivitis and goblet cell
density. J Ocul Pharmacol Ther. 2005;21(5):400–5. 44. Daniell M, Constantinou M, Vu HT, Taylor HR.
Randomised controlled trial of topical ciclosporin A
31. Spector SL, Raizman MB. Conjunctivitis in steroid dependent allergic conjunctivitis. Br J
medicamentosa. J Allergy Clin Immunol. 1994; Ophthalmol. 2006;90(4):461–4.
94(1):134–6.
45. Ozcan AA, Ersoz TR, Dulger E. Management of severe
32. Leonardi A, Busato F, Fregona I, et al. Anti- allergic conjunctivitis with topical cyclosporin a
inflammatory and antiallergic effects of ketorolac 0.05% eyedrops. Cornea. 2007;26(9):1035–8.
tromethamine in the conjunctival provocation
model. Br J Ophthalmol. 2000;84(11):1228–32. 46. Ebihara N, Ohashi Y, Uchio E, et al. A large
prospective observational study of novel
33. Gupta S, Khurana AK, Ahluwalia BK, Gupta NC. Topical cyclosporine 0.1% aqueous ophthalmic solution
indomethacin for vernal keratoconjunctivitis. Acta in the treatment of severe allergic conjunctivitis.
Ophthalmol (Copenh). 1991;69(1):95–8. J Ocul Pharmacol Ther. 2009;25(4):365–72.
34. Sharma A, Gupta R, Ram J, Gupta A. Topical 47. Wan KH, Chen LJ, Rong SS, et al. Topical Cyclo-
ketorolac 0.5% solution for the treatment of sporine in the Treatment of Allergic Conjunctivitis:
vernal keratoconjunctivitis. Indian J Ophthalmol. A Meta-analysis. Ophthalmology. 2013.
1997;45(3):177–80.
48. Rikkers SM, Holland GN, Drayton GE, et al. Topical
35. D’Angelo G, Lambiase A, Cortes M, et al. tacrolimus treatment of atopic eyelid disease. Am J
Preservative-free diclofenac sodium 0.1% for Ophthalmol. 2003;135(3):297–302.
vernal keratoconjunctivitis. Graefes Arch Clin Exp
Ophthalmol. 2003;241(3):192–5. 49. Vichyanond P, Tantimongkolsuk C,
Dumrongkigchaiporn P, et al. Vernal
36. McGhee CN, Dean S, Danesh-Meyer H. Locally keratoconjunctivitis: result of a novel therapy
administered ocular corticosteroids: benefits and with 0.1% topical ophthalmic FK-506 ointment.
risks. Drug Saf. 2002;25(1):33–55. J Allergy Clin Immunol. 2004;113(2):355–8.
37. Ang M, Ti SE, Loh R, et al. Steroid-induced ocular 50. Virtanen HM, Reitamo S, Kari M, Kari O. Effect of
hypertension in Asian children with severe vernal 0.03% tacrolimus ointment on conjunctival
keratoconjunctivitis.ClinOphthalmol.2012;6:1253–8. cytology in patients with severe atopic
123
88 Ophthalmol Ther (2013) 2:73–88
blepharoconjunctivitis: a retrospective study. Acta 63. Calderon MA, Penagos M, Sheikh A, et al.
Ophthalmol Scand. 2006;84(5):693–5. Sublingual immunotherapy for allergic conjunc-
tivitis: Cochrane systematic review and meta-
51. Attas-Fox L, Barkana Y, Iskhakov V, et al. Topical analysis. Clin Exp Allergy. 2011;41(9):1263–72.
tacrolimus 0.03% ointment for intractable allergic
conjunctivitis: an open-label pilot study. Curr Eye 64. Mahdy RA, Nada WM, Marei AA. Subcutaneous
Res. 2008;33(7):545–9. allergen-specific immunotherapy versus topical
treatment in vernal keratoconjunctivitis. Cornea.
52. Ohashi Y, Ebihara N, Fujishima H, et al. A 2012;31(5):525–8.
randomized, placebo-controlled clinical trial of
tacrolimus ophthalmic suspension 0.1% in severe 65. Holsclaw DS, Whitcher JP, Wong IG, Margolis TP.
allergic conjunctivitis. J Ocul Pharmacol Ther. Supratarsal injection of corticosteroid in the
2010;26(2):165–74. treatment of refractory vernal keratoconjunctivitis.
Am J Ophthalmol. 1996;121(3):243–9.
53. Labcharoenwongs P, Jirapongsananuruk O,
Visitsunthorn N, et al. A double-masked 66. Tanaka M, Takano Y, Dogru M, et al. A comparative
comparison of 0.1% tacrolimus ointment and 2% evaluation of the efficacy of intraoperative
cyclosporine eye drops in the treatment of vernal mitomycin C use after the excision of cobblestone-
keratoconjunctivitis in children. Asian Pac J Allergy like papillae in severe atopic and vernal
Immunol. 2012;30(3):177–84. keratoconjunctivitis. Cornea. 2004;23(4):326–9.
54. Akpek EK, Hasiripi H, Christen WG, Kalayci D. A 67. Fujishima H, Fukagawa K, Satake Y, et al. Combined
randomized trial of low-dose, topical mitomycin-C in medical and surgical treatment of severe vernal
the treatment of severe vernal keratoconjunctivitis. keratoconjunctivitis. Jpn J Ophthalmol. 2000;44(5):
Ophthalmology. 2000;107(2):263–9. 511–5.
55. Bielory L. Ocular symptom reduction in patients 68. Tanaka M, Dogru M, Takano Y, et al. Quantitative
with seasonal allergic rhinitis treated with the evaluation of the early changes in ocular surface
intranasal corticosteroid mometasone furoate. inflammation following MMC-aided papillary
Ann Allergy Asthma Immunol. 2008;100(3):272–9. resection in severe allergic patients with corneal
complications. Cornea. 2006;25(3):281–5.
56. Baroody FM, Shenaq D, DeTineo M, et al.
Fluticasone furoate nasal spray reduces the nasal- 69. Cameron JA. Shield ulcers and plaques of the
ocular reflex: a mechanism for the efficacy of topical cornea in vernal keratoconjunctivitis.
steroids in controlling allergic eye symptoms. Ophthalmology. 1995;102(6):985–93.
J Allergy Clin Immunol. 2009;123(6):1342–8.
70. Reddy JC, Basu S, Saboo US, et al. Management,
57. Weiner JM, Abramson MJ, Puy RM. Intranasal clinical outcomes, and complications of shield
corticosteroids versus oral H1 receptor antagonists ulcers in vernal keratoconjunctivitis. Am J
in allergic rhinitis: systematic review of randomised Ophthalmol. 2013;155(3):550–9 e1.
controlled trials. BMJ. 1998;317(7173):1624–9.
71. Sangwan VS, Jain V, Vemuganti GK, Murthy SI.
58. Bielory L, Lien KW, Bigelsen S. Efficacy and Vernal keratoconjunctivitis with limbal stem cell
tolerability of newer antihistamines in the deficiency. Cornea. 2011;30(5):491–6.
treatment of allergic conjunctivitis. Drugs.
2005;65(2):215–28. 72. Sangwan VS, Murthy SI, Vemuganti GK, et al.
Cultivated corneal epithelial transplantation for
59. Hingorani M, Lightman S. Therapeutic options in severe ocular surface disease in vernal
ocular allergic disease. Drugs. 1995;50(2):208–21. keratoconjunctivitis. Cornea. 2005;24(4):426–30.
60. Abelson MB, Butrus SI, Weston JH. Aspirin therapy 73. Sacchetti M, Lambiase A, Mantelli F, et al. Tailored
in vernal conjunctivitis. Am J Ophthalmol. approach to the treatment of vernal keratocon-
1983;95(4):502–5. junctivitis. Ophthalmology. 2010;117(7):1294–9.
61. Anzaar F, Gallagher MJ, Bhat P, et al. Use of 74. Leonardi A, Lazzarini D, Bortolotti M, et al. Corneal
systemic T-lymphocyte signal transduction confocal microscopy in patients with vernal
inhibitors in the treatment of atopic keratoconjunctivitis. Ophthalmology. 2011.
keratoconjunctivitis. Cornea. 2008;27(8):884–8.
75. Leonardi A, Lazzarini D, Bortolotti M, et al. Corneal
62. de Klerk TA, Sharma V, Arkwright PD. Biswas S. J AAPOS: confocal microscopy in patients with vernal
Severe vernal keratoconjunctivitis successfully treated keratoconjunctivitis. Ophthalmology. 2012;119(3):
with subcutaneous omalizumab; 2013. 509–15.
123